GHK-Cu is a copper-binding tripeptide naturally present in human plasma, peaking at ~200 ng/mL at age 20 and declining 60% to ~80 ng/mL by age 60. Over 50 years of research has documented 72+ distinct biological actions and the ability to activate or silence over 4,000 human genes — more than any other single compound studied.
A copper-binding tripeptide your body already makes — and progressively loses with age.
GHK-Cu is Glycyl-L-histidyl-L-lysine bound to a copper(II) ion. Found naturally in blood plasma (~200ng/mL at age 20), saliva, and urine. Three amino acids. One copper atom. Profound biology.
Dr. Loren Pickart discovered GHK when studying why old human plasma made old liver tissue behave like young tissue. That observation launched 50+ years of research into the compound's regenerative properties.
Plasma levels peak around age 20 (~200 ng/mL) and decline steadily to ~80 ng/mL by age 60 — a 60% reduction. This decline tracks with the deterioration of wound healing and tissue maintenance seen in aging.
The 2012 Pickart & Margolina review documented over 72 distinct biological actions — including stimulating collagen, elastin, glycosaminoglycans, and decorin production, while also acting as an anti-inflammatory and antioxidant.
GHK-Cu can activate or silence over 4,000 human genes — more than any other single compound studied to date. It appears to reset gene expression patterns toward a "younger" state, upregulating repair genes and downregulating inflammatory ones.
Same molecule. Radically different biodistribution. Here's what the data (and community) says about each route.
The injectable evidence gap: The strong clinical evidence for GHK-Cu comes almost entirely from topical studies. The injectable route has compelling theoretical rationale (systemic distribution, gene regulation) but lacks the same volume of controlled human trials. Anecdotal reports are mixed — some report remarkable results, experienced users say "does nothing injectable." Approach with appropriate expectations.
Beyond surface-level "anti-aging" claims — GHK-Cu has been shown to remodel gene expression at scale.
Upregulates genes involved in skin repair, wound healing, and extracellular matrix remodeling.
Downregulates inflammatory pathways including TNF-α, IL-6, and other pro-inflammatory cytokines.
Superoxide dismutase-like activity. Reduces oxidative damage from free radicals in tissue.
GHK-Cu has been shown to restore normal behavior in cancer cells. Silences metastasis genes in early research.
The latest clinical data and mechanistic discoveries — connecting GHK-Cu to longevity pathways and confirming its wound-healing prowess.
Researchers discovered GHK-Cu significantly upregulates SIRT1 expression — the "longevity gene" central to cellular aging. Molecular docking analysis showed strong binding affinity between GHK-Cu and SIRT1. This positions GHK-Cu as a novel SIRT1 activator, connecting it to the NAD+/sirtuin pathway that drives cellular metabolism and lifespan extension in model organisms.
A multicenter human trial tested 0.05% GHK-Cu gel following fractional laser resurfacing. Results: 25% faster epithelial recovery versus standard care, with visible redness reduced within 72 hours. Inflammatory markers IL-1β and TNF-alpha decreased by 30% — confirming the anti-inflammatory mechanism in real-world clinical application.
2024 Caution Finding — MMP-1 Expression: Research also found GHK-Cu may enhance MMP-1 (matrix metalloproteinase-1) expression. MMP-1 is associated with collagen fragmentation in aging skin — the very thing GHK-Cu supposedly prevents. This represents a potential double-edged sword: GHK-Cu may promote collagen synthesis while simultaneously enhancing enzymes that break it down. More research is needed to understand the net effect in different contexts.
The Age Decline Significance: At age 20, plasma GHK-Cu runs around 200 ng/mL. By age 60, it's dropped to approximately 80 ng/mL — a 60% reduction. This decline tracks closely with the deterioration of wound healing, collagen production, and tissue maintenance observed in aging. The rationale for supplementation: restore youthful GHK-Cu levels to support the body's natural repair mechanisms.
Copper and zinc compete for the same absorption transporter. This isn't optional reading.
Copper-Zinc Competition: Both copper and zinc use the same intestinal transporter (metallothionein). Supplementing copper (as in GHK-Cu) can deplete zinc over time. Zinc deficiency affects immune function, testosterone, wound healing, and cognitive function — everything you're probably trying to optimize.
If running GHK-Cu injectable (1-2mg/day), supplement with 15-30mg elemental zinc daily, away from copper supplementation (separate by several hours if possible).
⚕️ Always consult a healthcare provider before starting any peptide protocol.
GHK-Cu has an unusually strong evidence base for topical use. Injectable is more complicated.
Pickart, L., & Margolina, A. (2012). Restorative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. — This review documents 72 biological actions and the gene regulation findings referenced throughout this page.
Third-party tested compounds from Swiss Chems — one of the most trusted research suppliers.
Affiliate link — supports MeetPeptide at no extra cost. All Swiss Chems products include third-party lab testing certificates.
Relevant supplies for GHK-Cu topical and injectable protocols
Affiliate links help support MeetPeptide at no extra cost to you.
Self-Assessment
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.